Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CohMSM-PrEP
NCT03459157Completed
- Sponsor
- ANRS
- Start
- Nov 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Open-label, single-arm trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV), sponsored by ANRS. Primary endpoints: Percentage of MSM under PrEP among eligible HIV-seronegative participants at 3 years, Percentage of MSM using daily and/or on-demand PrEP at 3 years and 14 more. Started Nov 2017; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03459157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459157.